Recent Company News

• 06:20 PM ET Oct 30, 2025
  

  Biophytis reports H1 net income (€3.5M) vs year-ago (€5.8M) (€0.11, 0.00)

• 04:16 AM ET Sep 01, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:09 AM ET Oct 13, 2025
  

  Biophytis and a consortium of Asian investors plan to form JV to develop and exclusively commercialize BIO101 in China, Japan, and Korea (€0.15, 0.00)

• 01:04 AM ET Sep 15, 2025
  

  Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs agreements with Leading local Clinical Partners (€0.17, 0.00)

• 01:03 AM ET Sep 11, 2025
  

  Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia (€0.17, 0.00)

• 01:02 AM ET Sep 03, 2025
  

  Biophytis obtains EMA authorization to launch its Phase 2 clinical trial of BIO101 in obesity (€0.18, 0.00)

• 01:06 AM ET Sep 01, 2025
  

  Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil (€0.17, 0.00)